ELAB
Price
$2.61
Change
+$0.05 (+1.95%)
Updated
Dec 23, 04:59 PM (EDT)
LXRX
Price
$0.82
Change
+$0.11 (+15.49%)
Updated
Dec 23, 04:59 PM (EDT)
79 days until earnings call
Ad is loading...

ELAB vs LXRX

Header iconELAB vs LXRX Comparison
Open Charts ELAB vs LXRXBanner chart's image
PMGC Holdings
Price$2.61
Change+$0.05 (+1.95%)
Volume$1.02K
CapitalizationN/A
Lexicon Pharmaceuticals
Price$0.82
Change+$0.11 (+15.49%)
Volume$132.79K
CapitalizationN/A
ELAB vs LXRX Comparison Chart
Loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAB vs. LXRX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and LXRX is a Hold.

COMPARISON
Comparison
Dec 24, 2024
Stock price -- (ELAB: $2.56 vs. LXRX: $0.71)
Brand notoriety: ELAB and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 88% vs. LXRX: 154%
Market capitalization -- ELAB: $7.87M vs. LXRX: $298.95M
ELAB [@Biotechnology] is valued at $7.87M. LXRX’s [@Biotechnology] market capitalization is $298.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $363.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 1 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • ELAB’s FA Score: 1 green, 4 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 5 TA indicator(s) are bullish while LXRX’s TA Score has 5 bullish TA indicator(s).

  • ELAB’s TA Score: 5 bullish, 2 bearish.
  • LXRX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, both ELAB and LXRX are a good buy in the short-term.

Price Growth

ELAB (@Biotechnology) experienced а +11.79% price change this week, while LXRX (@Biotechnology) price change was -11.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.79%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +3.59%.

Reported Earning Dates

LXRX is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-1.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($299M) has a higher market cap than ELAB($7.87M). LXRX YTD gains are higher at: -53.288 vs. ELAB (-99.300). ELAB has higher annual earnings (EBITDA): -4.75M vs. LXRX (-198.7M). LXRX has more cash in the bank: 258M vs. ELAB (6.43M). ELAB has less debt than LXRX: ELAB (103K) vs LXRX (101M). LXRX has higher revenues than ELAB: LXRX (5.23M) vs ELAB (2.45M).
ELABLXRXELAB / LXRX
Capitalization7.87M299M3%
EBITDA-4.75M-198.7M2%
Gain YTD-99.300-53.288186%
P/E RatioN/AN/A-
Revenue2.45M5.23M47%
Total Cash6.43M258M2%
Total Debt103K101M0%
FUNDAMENTALS RATINGS
LXRX: Fundamental Ratings
LXRX
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
24
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABLXRX
RSI
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 15 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
67%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVFKX79.361.11
+1.42%
Smead Value R2
TOCQX47.040.57
+1.23%
Tocqueville
ADJEX16.360.17
+1.05%
Azzad Ethical
QISCX27.060.24
+0.89%
Federated Hermes MDT Small Cap Core IS
LHCSX19.290.01
+0.05%
Lord Abbett Health Care R4

ELAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAB has been loosely correlated with EPIX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAB jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
+8.94%
EPIX - ELAB
33%
Loosely correlated
N/A
REGN - ELAB
21%
Poorly correlated
-0.90%
MTNB - ELAB
20%
Poorly correlated
-3.81%
LXRX - ELAB
20%
Poorly correlated
-1.23%
ENGN - ELAB
17%
Poorly correlated
-2.18%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with EPIX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-1.23%
EPIX - LXRX
44%
Loosely correlated
N/A
FRTX - LXRX
41%
Loosely correlated
-0.34%
NTLA - LXRX
37%
Loosely correlated
+0.83%
BEAM - LXRX
37%
Loosely correlated
+8.04%
SPRO - LXRX
37%
Loosely correlated
-4.30%
More